Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Tefibazumab
Подписчиков: 0, рейтинг: 0
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Clumping factor A |
Clinical data | |
Trade names | Aurexis |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6548H10122N1730O2034S44 |
Molar mass | 147035.72 g·mol−1 |
NY (what is this?) (verify) |
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.
It was developed by Inhibitex.
See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
Fungal |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Viral | |||||||||
Bacterial |
|
||||||||
Toxin |
|
||||||||
|